Trial Profile
A retrospective pharmacovigilance study based on VigiBase- to identify and characterize immune checkpoint inhibitors-associated Nephrotoxicity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Gastrointestinal cancer; Haematological malignancies; Head and neck cancer; Kidney-neoplasms; Lung cancer; Skin cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- 02 Jun 2021 New trial record
- 24 May 2021 Results published in the Nephrology Dialysis Transplantation